Oxaliplatin (Foloxatine, Transplatin, Eloxatin, Eloxatine, Elplat, RP-54780, NSC-266046, NSC-271670, Dacplat, D01790, Oxalatoplatin, Oxalatoplatinum, Oxalato(1R,2R-cyclohexanediamine)platinum(II),CAS 61825-94-3), >99%

LC Laboratories' Product Number O-7111 - Oxaliplatin (Foloxatine, Transplatin, Eloxatin, Eloxatine, Elplat, RP-54780, NSC-266046, NSC-271670, Dacplat, D01790, Oxalatoplatin, Oxalatoplatinum, Oxalato(1R,2R-cyclohexanediamine)platinum(II), CAS 61825-94-3), >99% - for research use only. Oxaliplatin is a a third-generation, diaminocyclohexane-containing platinum anti-cancer drug. It is typically used in combination with fluorouracil (5-FU) and leucovorin, known as FOLFOX, for the treatment of colorectal cancer. The leucovorin-modulated single-agent 5-FU regimens achieved a median overall survival of 15 months or less. Combination regimens of FOLFOX consistently lead to median survivals in the 15 to 20-month range. Oxaliplatin has different antitumor spectrum, mechanisms of action, and resistance from the other platinum-containing compounds, notably cisplatin. The anticancer activity and the antitumor specificity of oxaliplatin mainly depend on human organic cation transporters (OCT) 1 and OCT2. The oxaliplatin cytotoxicity depends on MKK7/JNK, while SEK1 might be involved in hypoxic resistance to oxaliplatin. Oxaliplatin is the active ingredient in the drug sold under the trade name Eloxatin®. This drug has been approved in at least one country for use in patients with colorectal cancer.

• Supplier: LC Laboratories
• Product #: O-7111
• Sku #: O-7111_300mg